A. Enasidenib B. Ivosidenib C. Vorasidenib D. None of the above E. Unsure

A. The rate of complete remission (CR) or CR with partial hematologic recovery was 30%, with a median time to response of 2.7 months B. The rate of CR or CR with partial hematologic recovery was 40%, with those obtaining a CR having a longer overall survival time C. The rate of CR or CR with partial hematologic recovery was 43%, and 10% of patients proceeded to hematopoietic stem cell transplantation D. Among patients who were transfusion-dependent at baseline, most (85%) were transfusion independent by 90 days E. Unsure

A. Continue ivosidenib and start antibiotics; closely monitor AL's signs and symptoms B. Discontinue ivosidenib permanently C. Initiate dexamethasone 10 mg by mouth twice daily; continue ivosidenib with close monitoring D. Interrupt ivosidenib and start hydroxyurea E. Unsure

A. Differentiation syndrome, myelosuppression, and nausea B. Diarrhea, hyperbilirubinemia, and nausea C. Fatigue, noninfectious leukocytosis, and QTc prolongation D. Hyperbilirubinemia, abdominal pain, and nausea E. Unsure

A. Take enasidenib with food to prevent side effects B. Avoid taking enasidenib with a high-fat meal to prevent side effects C. Order prophylactic corticosteroids to prevent differentiation syndrome D. Administer prophylactic antiemetic before administration of enasidenib to prevent nausea and vomiting E. Unsure